Table 3.
Ongoing clinical trials
| Title | Study population | Phase | Treatment | Primary outcome | Secondary outcome | |
|---|---|---|---|---|---|---|
| Advanced/Induction | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer [NCT02635360] | Locally advanced cervical cancer | II | Pembrolizumab with CRT | Change in immunologic markers, DLT | Metabolic response rate on PET/CT, incidence of distant metastasis, PFS, OS |
| TSR-042 (Dostralimab) as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC) [NCT03833479] | Stage IB/IIA/IIB/III/IVA cervical cancer with pelvic and para-aortic lymph nodes | II | CRT, maintenance dostarlimab | PFS | AE, OS | |
| Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients with Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer [NCT03738228] | Stage IB/II cervical cancer with PALN or IIB/III/IVA cervical cancer with pelvic or para-aortic lymph nodes | I | Atezolizumab with CRT, atezolizumab before CRT | DLT | DFS, AE, ORR, PFS | |
| Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) [NCT03612791] | Locally advanced cervical cancer | II | Atezolizumab with CRT and adjuvant atezolizumab | PFS | ||
| Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer [NCT05492123] | Stage IB2II-IB3 with positive nodes, or stage IIB-IVA | II | Nivolumab/ipilimumab induction with CRT | PFS | ORR, OS, HRQOL, AE, DOR | |
| Recurrent/Metastatic | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) [NCT03556839] | Metastatic/persistent/recurrent | III | Platinum/taxane/bevacizumab +/− atezolizumab | PFS, OS | ORR, DOR, AE, FST, PFS, HRQOL |
| Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer (FERMATA) [NCT03912415] | Metastatic/persistent/recurrent | III | BCD-100 (anti-PD-1) + platinum/taxane +/− bevacizumab | OS | PFS, ORR, DCR, TTR, DOR | |
| Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (STAR) [NCT04068753] | Recurrent/ progressive | II | Niraparib + dostarlimab | Proportion of patients with response | AE, DOR, PFS, OS | |
| Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer (CQGOG0101) [NCT04395612] | Recurrent/ progressive | II | Niraparib + brivanib or toripalimab | ORR | PFS, DCR | |
| Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium (Clovis-001) [NCT03476798] | Recurrent/ progressive | II | Rucaparib + bevacizumab | PFS | ORR, AE, OS | |
| Anti-PD-1 Independently or in Combination with Anti-CTLA-4 in Second-line Cervical Cancer (RaPiDS) [NCT03894215] | Recurrent/ progressive | II | Balstilimab + zalifrelimab | ORR | DOR, AE |
CRT: chemoradiation; PALN: para-aortic lymph nodes; PFS: progression-free survival; AE: adverse event; OS; overall survival; DLT: dose limiting toxicity; ORR: objective response rate, DOR: duration of response; FST: first subsequent therapy; TTR: time to response; DCR: disease control rate; HRQOL: health-related quality of life; PET: positron emission tomography; CT: computed tomography; DFS: disease-free survival; PD-1: programmed cell death protein-1; CTLA-4: cytotoxic T-lymphocyte-associated protein 4.